logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 5
  • 1
    Chan, Chi Ming
    Born in October 1961
    Individual (3 offsprings)
    Officer
    icon of calendar 2014-10-09 ~ now
    OF - Director → CIF 0
  • 2
    Doogan, Declan, Dr
    Born in March 1952
    Individual (2 offsprings)
    Officer
    icon of calendar 2015-10-01 ~ now
    OF - Director → CIF 0
  • 3
    Habib, Nagy, Professor
    Born in August 1952
    Individual (28 offsprings)
    Officer
    icon of calendar 2011-03-29 ~ now
    OF - Director → CIF 0
  • 4
    Habib, Robert Sebastian
    Born in November 1985
    Individual (5 offsprings)
    Officer
    icon of calendar 2014-10-09 ~ now
    OF - Director → CIF 0
  • 5
    Bains, Peter James Jonathan
    Born in July 1957
    Individual (8 offsprings)
    Officer
    icon of calendar 2019-03-06 ~ now
    OF - Director → CIF 0
Ceased 2
  • 1
    Hakimzadeh, Karim
    Investor born in May 1986
    Individual (5 offsprings)
    Officer
    icon of calendar 2019-12-02 ~ 2022-04-05
    OF - Director → CIF 0
  • 2
    Nicholls, Joanna Patricia
    Research Manager born in May 1954
    Individual (6 offsprings)
    Officer
    icon of calendar 2012-02-03 ~ 2014-07-31
    OF - Director → CIF 0
parent relation
Company in focus

APTERNA LIMITED

Previous name
HCC RNA THERAPEUTICS LIMITED - 2013-08-20
Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
52023-04-01 ~ 2024-03-31
52022-04-01 ~ 2023-03-31
Debtors
Current
31,105 GBP2024-03-31
4,125 GBP2023-03-31
Cash at bank and in hand
26,149 GBP2024-03-31
53,364 GBP2023-03-31
Current Assets
57,254 GBP2024-03-31
57,489 GBP2023-03-31
Creditors
Current, Amounts falling due within one year
-49,113 GBP2024-03-31
Net Current Assets/Liabilities
8,141 GBP2024-03-31
3,766 GBP2023-03-31
Total Assets Less Current Liabilities
8,141 GBP2024-03-31
3,766 GBP2023-03-31
Net Assets/Liabilities
8,141 GBP2024-03-31
3,766 GBP2023-03-31
Equity
Called up share capital
3 GBP2024-03-31
3 GBP2023-03-31
3 GBP2022-04-01
Share premium
2,332,111 GBP2024-03-31
2,282,153 GBP2023-03-31
2,282,153 GBP2022-04-01
Retained earnings (accumulated losses)
-2,323,973 GBP2024-03-31
-2,278,390 GBP2023-03-31
-2,221,122 GBP2022-04-01
Equity
8,141 GBP2024-03-31
3,766 GBP2023-03-31
61,034 GBP2022-04-01
Profit/Loss
Retained earnings (accumulated losses)
-45,583 GBP2023-04-01 ~ 2024-03-31
-57,268 GBP2022-04-01 ~ 2023-03-31
Profit/Loss
-45,583 GBP2023-04-01 ~ 2024-03-31
-57,268 GBP2022-04-01 ~ 2023-03-31
Comprehensive Income/Expense
Retained earnings (accumulated losses)
-45,583 GBP2023-04-01 ~ 2024-03-31
-57,268 GBP2022-04-01 ~ 2023-03-31
Comprehensive Income/Expense
-45,583 GBP2023-04-01 ~ 2024-03-31
-57,268 GBP2022-04-01 ~ 2023-03-31
Issue of Equity Instruments
49,958 GBP2023-04-01 ~ 2024-03-31
Equity - Income/Expense Recognised Directly
49,958 GBP2023-04-01 ~ 2024-03-31
Audit Fees/Expenses
6,000 GBP2023-04-01 ~ 2024-03-31
6,000 GBP2022-04-01 ~ 2023-03-31
Other Debtors
Current
6,938 GBP2024-03-31
4,125 GBP2023-03-31
Prepayments/Accrued Income
Current
24,167 GBP2024-03-31
Cash and Cash Equivalents
26,149 GBP2024-03-31
53,364 GBP2023-03-31
Trade Creditors/Trade Payables
Current
31,360 GBP2024-03-31
22,078 GBP2023-03-31
Other Creditors
Current
25,195 GBP2023-03-31
Accrued Liabilities/Deferred Income
Current
17,753 GBP2024-03-31
6,450 GBP2023-03-31
Creditors
Current
49,113 GBP2024-03-31
53,723 GBP2023-03-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
1,065,084 shares2024-03-31
1,056,163 shares2023-03-31
Par Value of Share
Class 1 ordinary share
0.0000032023-04-01 ~ 2024-03-31
Number of Shares Issued (Fully Paid)
Class 2 ordinary share
173,265 shares2024-03-31
173,265 shares2023-03-31
Par Value of Share
Class 2 ordinary share
0.0000032023-04-01 ~ 2024-03-31
Number of Shares Issued (Fully Paid)
Class 3 ordinary share
40,000 shares2024-03-31
40,000 shares2023-03-31
Par Value of Share
Class 3 ordinary share
0.0000012023-04-01 ~ 2024-03-31

  • APTERNA LIMITED
    Info
    HCC RNA THERAPEUTICS LIMITED - 2013-08-20
    Registered number 07583272
    icon of address1 Vincent Square, London SW1P 2PN
    PRIVATE LIMITED COMPANY incorporated on 2011-03-29 (14 years 9 months). The company status is Active.
    The last date of confirmation statement was made at 2025-03-29
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022-2025 Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 12 November 2025 and licensed under the Open Government Licence v3.0.